Alessandro Rametta

Medical Oncologist at IRCCS Istituto Nazionale Tumori di Milano @IstTumori - Genitourinary Medical Oncology Department

[Giuseppe Procopio @g_procopio_]

🔬 New evidence in #mHSPC
PSA nadir ≤0.2 ng/mL was strongly associated with better outcomes:
📈 OS: 92.8 vs 34 mo (HR 0.27)
📈 PFS: NR vs 12.1 mo (HR 0.19) Supporting PSA nadir as an early prognostic marker. #ProstateCancer #GUOncology
Full Article: https://t.co/3KgAAaukPr

[Giuseppe Procopio @g_procopio_]

New data in @ESMO_Open : among 59 centrally reviewed collecting duct carcinoma cases, Trop-2 was expressed in 89% and Nectin-4 in 41%, supporting further investigation of antibody-drug conjugates in this rare disease.

https://t.co/wuuASnfr0b

#KidneyCancer #RareCancer

[Giuseppe Procopio @g_procopio_]

Does local treatment of the primary tumour still add value in #mHSPC patients receiving ARPIs? Our latest expert opinion examines the evidence, ongoing controversies and future directions in the intensification era.

Article here: https://t.co/J1UAPcx9dI

#Genitourinary #Prostate

[Giuseppe Procopio @g_procopio_]

The 3rd General Assembly of the European @CARE1Project has officially started today @IstTumori!
Partners from across Europe are meeting to share progress and strengthen collaboration in kidney cancer research

#CARE1 #KidneyCancer #Oncology #CancerResearch #EUProjects

[OncoDaily GU @OncoDailyGU]

🔟 Must-Read Posts in GU Oncology | May 1–10
OncoDaily GU highlights key updates across prostate, bladder, kidney, testicular, and penile cancers.

This week:
• PSMAfore / Pluvicto — regulatory update in earlier-line mCRPC
• DEAR-EXT — real-world AR inhibitor analysis in nmCRPC
• P-PSMA-101 CAR T — Phase I study in mCRPC
• ¹⁷⁷Lu-PSMA-617 — review on immune modulation
• Radiorecurrent prostate cancer — salvage local therapies
• Stage IIIC poor-risk testicular GCT — high-risk cohort
• AI in bladder cancer — clinical decision-making
• NBI-guided diode laser ablation — recurrent low-grade NMIBC
• Metastatic non-clear cell RCC — multicenter retrospective analysis
• B7-H3/CD276 in penile cancer — bispecific antibody strategy, including CC-3

@nealshore @Igor__Tsaur @DrShariat @alerametta
@g_procopio_ @marcos130990 @Sebastiano_Buti @crisuarez08 @therealmarcodoc @fmassari79 @DrIacovelli @MatteoSantoniMD @CMucciarini_Dr
@g_procopio_ @drenriquegrande @YLeyfman @oncodaily

📎 https://t.co/7Mu1T27TXa

#OncoDailyGU #GUOncology #ProstateCancer #BladderCancer #KidneyCancer #UroOncology

[Alessandro Rametta @alerametta]

Our study is now online!

“International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma” is now published in @TumoriJ.

👉 https://t.co/bZioyHWzD4

A large international retrospective analysis of metastatic non–clear cell RCC based on Vall d’Hebron and Italian Meet-URO network @meeturoIT.

Thanks to all co-authors and collaborators!

@g_procopio_ @marcos130990 @Sebastiano_Buti @crisuarez08 @therealmarcodoc @fmassari79 @DrIacovelli @MatteoSantoniMD @CMucciarini_Dr

[Giuseppe Procopio @g_procopio_]

New publication where we explore the rationale and clinical implications of continuing angiogenesis inhibition beyond progression in #mRCC.
Full article here:
https://t.co/at2d69Q4gG

#ClinicalResearch #Genitourinary #oncology

[Amedeo Nuzzo @nzzmda]

🧵New commentary in @JCOOP_ASCO on metastatic Renal Cell Carcinoma:

“Never Stop the Pressure” 🔬

Should we keep anti-angiogenic therapy going beyond progression?

We think YES — and here’s why👇
https://t.co/B4FglO8h74

w/ @alerametta @elena_verzoni @g_procopio_

[Alessandro Rametta @alerametta]

4 febbraio – Giornata mondiale contro il cancro.

Prevenzione, vaccinazioni e screening riducono il rischio oncologico e permettono diagnosi precoci. Sono strumenti semplici e disponibili, che possono fare la differenza.

[Alessandro Rametta @alerametta]

Machine Learning to predict response to IO in 438 patients with metastatic urothelial carcinoma from Italian @meeturoIT network. Results are exploratory but clinically coherent.

AI can play an important role in GU oncology. Better data quality and wider implementation of these approaches are essential.

Thanks to @PrelajArsela, @polimi and all the @AI_ON_Lab for this work.

@giannatempopatr @g_procopio_ @marcos130990 @AndreaNecchi @Vanja_Miskovic_

Out on ESMO RWD and DO: https://t.co/ufXIG9Fi5A

[Giuseppe Procopio @g_procopio_]

Innovation talk at @IstTumori with @alerametta: machine learning and artificial intelligence in GU tumors, how data and algorithms can improve diagnosis and treatment.

#AIinMedicine #ClinicalResearch #Oncology #Genitourinary #ScientificEvent #ControversiesinGU2026

[Giuseppe Procopio @g_procopio_]

A full day of debate, evidence and shared perspectives comes to an end at @IstTumori. Thank you to all speakers, participants and partners for contributing to "Controversies in Genitourinary Tumors". See you next year!

#ClinicalResearch #GUoncology #ControversiesinGU2026

[Alessandro Rametta @alerametta]

How do we actually treat non–clear cell RCC today?

Our practical overview of systemic therapies across rare renal cancer histologies.

https://t.co/aITNVUFrCF

@g_procopio_ @elena_verzoni @marcos130990 @MelClaps @valentina79g @nzzmda @Simorota6 @elegusma

[Tom Powles @tompowles1]

A review in @NatRevClinOncol @scocmem covers whats next for FGFR in bladder cancer. FORAGER-2 explores EV + pembro + Vepugratinib (FGFR inhibitor with short half life) in 1st line FGFR3 altered advanced UC. Targeted/ADC/PD1 triplets curing UC? @OncoAlert @DrChoueiri @PGrivasMDPhD

[Sarah Scagliarini, MD @SScagliarini_]

#ESMO25 #MIBC #BladderCancer
➡️ Perioperative Pembro + EV.
😶 No words.
👏🏼 Just applause.
📣 Sound On.
@myESMO

[Tom Powles @tompowles1]

1/2 Disitimab Vedotin & toripalimab beating platinum chemotherapy in 1st line UC in HER2 +ves. HRs for PFS/OS =0.36/0.56 respectively. RR and CR rate of 76% & 5% respectively. Tox related discontinuation in 12 vs 10% respectively. Working across all subsets #ESMO25 @OncoAlert

[Amedeo Nuzzo @nzzmda]

📢 Our case report on metastatic Leydig cell tumor treated with CDK4 inhibition is now published in JCO Precision Oncology!
👉 https://t.co/guZsfNBcUJ

A collaborative effort with @JCOPO_ASCO @giannatempopatr @nicolanicolai @AndreaNecchi @montypal

[Guillermo de Velasco @g_develasco]

IMvigor011
𝗰𝘁𝗗𝗡𝗔+ → 𝗢𝗦/𝗣𝗙𝗦 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝘄𝗶𝘁𝗵 𝗮𝘁𝗲𝘇𝗼
𝗰𝘁𝗗𝗡𝗔– → 𝘀𝗽𝗮𝗿𝗲𝗱 𝘂𝗻𝗻𝗲𝗰𝗲𝘀𝘀𝗮𝗿𝘆 𝗜𝗢
Primum non nocere: treating only those with molecular evidence of disease. This is Huge!
Congrats to @tompowles1 and everyone involved 👏

[Tom Powles @tompowles1]

Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC https://t.co/MEsZvzktTe